

A generic equivalent to PrVolibris*

- > Packaged in unit-dose blisters of 30 tablets
- > Approved as monotherapy or in combination with tadalafil

| Appearance | Strength | DIN | Format | UPC |
|----------------------------------------------------|---------------------------------|----------|-------------------------------------------------|-----------------|
| PrSandoz® Ambrisentan Tablets 5 PrVolibris* | 5 mg Film-coated tablets | 02526875 | Unit-dose blisters of 30 (3 x 10 tablets) | 0 57513 22240 5 |
| PrSandoz® Ambrisentan Tablets PrVolibris* KE3 GS | 10 mg Film-coated tablets | 02526883 | Unit-dose blisters of 30 (3 x 10 tablets) | 0 57513 22241 2 |

^{™/®} Trademark and registered trademark owned or used under license by Sandoz Canada Inc.

Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636.



^{*} Registered trademark owned by its respective registrant.

PrSandoz® Ambrisentan Tablets



Support you can trust

Why choose Sandoz Continüm™?



SPEED

24-hour turnaround for enrolment



SIMPLICITY

Easy-to-complete enrollment form that requires only one signature, the patient's consent



EFFICIENCY

Electronic coverage speeds up payment process

What services are offered for PrSandoz® Ambrisentan Tablets†

Our experienced team of patient access specialists provide:



REIMBURSEMENT NAVIGATION

Regional expertise to help complete coverage requests



FINANCIAL ASSISTANCE

Financial support available, tailored to each patient's situation













For any questions or to obtain the enrollment form, please contact Sandoz Continüm™ at 1-888-6-SANDOZ (726369) or visit sandoz.ca/en/psp.

Please consult Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636.



^{™/®} Trademark and registered trademark owned or used under license by Sandoz Canada Inc.

[†] Provincial exclusions may apply due to regulatory or other considerations.

^{Pr}Sandoz[®] Ambrisentan Tablets is indicated for treatment of idiopathic ('primary') pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in adult patients with WHO functional class II or III symptoms and also indicated for initiation therapy in combination with tadalafil.